Mingus
Well-known member
[SIZE=-1] http://www.jimmunol.org/cgi/content/abstract/176/2/1122
The Journal of Immunology, 2006, 176: 1122-1130.
Copyright ? 2006 by The American Association of Immunologists [/SIZE]
Modified Pulmonary Surfactant Is a Potent Adjuvant That Stimulates the Mucosal IgA Production in Response to the Influenza Virus Antigen<sup>1</sup>
<nobr>Dai Mizuno</nobr>, <nobr>Mikiko Ide-Kurihara</nobr>, <nobr>Tomoko Ichinomiya</nobr>, <nobr>Itsuka Kubo</nobr> and <nobr>Hiroshi Kido<sup>2</sup></nobr> [SIZE=-1] Division of Enzyme Chemistry, Institute for Enzyme Research, University of Tokushima, Tokushima, Japan [/SIZE]
<!-- ABS --> The intranasal administration of influenza hemagglutinin (HA)<sup> </sup>vaccine with Surfacten, a modified pulmonary surfactant free<sup> </sup>of antigenic c-type lectins, as a mucosal adjuvant induced the<sup> </sup>highest protective mucosal immunity in the airway. The intranasal<sup> </sup>immunization of mice with HA vaccine (0.2 ?g)-Surfacten<sup> </sup>(0.2 ?g) selectively induced the neutralizing anti-HA<sup> </sup>IgA, but not IgG, and conferred nearly maximal protection in<sup> </sup>the airway, without inducing a systemic response. In contrast,<sup> </sup>intranasal inoculation of vaccine with 0.2 ?g of the potent<sup> </sup>mucosal adjuvant cholera toxin B* (CT-B*), prepared by adding<sup> </sup>0.2% native CT to the B subunit of CT, induced both anti-HA<sup> </sup>IgA and IgG in the airway and in the serum. The intranasal administration<sup> </sup>of HA vaccine alone induced a limited amount of mucosal IgA<sup> </sup>against influenza virus. Although the s.c. administration of<sup> </sup>HA vaccine prominently induced serum IgG and IgA, Surfacten<sup> </sup>and CT-B* did not enhance their induction, and the concentrations<sup> </sup>of Abs leaking into the airways were insufficient to prevent<sup> </sup>viral multiplication. The intranasal administration of HA-Surfacten<sup> </sup>stimulated the expression of MHC class II, CD40, and CD86 molecules<sup> </sup>in the CD11c-positive cells isolated from the nasal mucosa,<sup> </sup>but not the expression of cells from the lungs or spleens. Lymphocytes<sup> </sup>isolated from the airway mucosa after intranasal HA-Surfacten<sup> </sup>immunization prominently induced TGF-
1 which, compared with<sup> </sup>inoculation without Surfacten, promoted an Ag-specific mucosal<sup> </sup>IgA response. Surfacten alone, however, did not induce TGF-
1.<sup> </sup>Our observations suggest that Surfacten, by mimicking the natural<sup> </sup>surfactant, is an effective mucosal adjuvant in the process<sup> </sup>of airway immunization.
The Journal of Immunology, 2006, 176: 1122-1130.
Copyright ? 2006 by The American Association of Immunologists [/SIZE]
Modified Pulmonary Surfactant Is a Potent Adjuvant That Stimulates the Mucosal IgA Production in Response to the Influenza Virus Antigen<sup>1</sup>
<nobr>Dai Mizuno</nobr>, <nobr>Mikiko Ide-Kurihara</nobr>, <nobr>Tomoko Ichinomiya</nobr>, <nobr>Itsuka Kubo</nobr> and <nobr>Hiroshi Kido<sup>2</sup></nobr> [SIZE=-1] Division of Enzyme Chemistry, Institute for Enzyme Research, University of Tokushima, Tokushima, Japan [/SIZE]
<!-- ABS --> The intranasal administration of influenza hemagglutinin (HA)<sup> </sup>vaccine with Surfacten, a modified pulmonary surfactant free<sup> </sup>of antigenic c-type lectins, as a mucosal adjuvant induced the<sup> </sup>highest protective mucosal immunity in the airway. The intranasal<sup> </sup>immunization of mice with HA vaccine (0.2 ?g)-Surfacten<sup> </sup>(0.2 ?g) selectively induced the neutralizing anti-HA<sup> </sup>IgA, but not IgG, and conferred nearly maximal protection in<sup> </sup>the airway, without inducing a systemic response. In contrast,<sup> </sup>intranasal inoculation of vaccine with 0.2 ?g of the potent<sup> </sup>mucosal adjuvant cholera toxin B* (CT-B*), prepared by adding<sup> </sup>0.2% native CT to the B subunit of CT, induced both anti-HA<sup> </sup>IgA and IgG in the airway and in the serum. The intranasal administration<sup> </sup>of HA vaccine alone induced a limited amount of mucosal IgA<sup> </sup>against influenza virus. Although the s.c. administration of<sup> </sup>HA vaccine prominently induced serum IgG and IgA, Surfacten<sup> </sup>and CT-B* did not enhance their induction, and the concentrations<sup> </sup>of Abs leaking into the airways were insufficient to prevent<sup> </sup>viral multiplication. The intranasal administration of HA-Surfacten<sup> </sup>stimulated the expression of MHC class II, CD40, and CD86 molecules<sup> </sup>in the CD11c-positive cells isolated from the nasal mucosa,<sup> </sup>but not the expression of cells from the lungs or spleens. Lymphocytes<sup> </sup>isolated from the airway mucosa after intranasal HA-Surfacten<sup> </sup>immunization prominently induced TGF-